

Attorney Docket No.: 5885.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Callisen et al.

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: December 3, 2001

Examiner: To be assigned

For: Chemically Modified Lipolytic enzyme

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. EP 0 258 068
2. EP 0 305 216
3. WO 92/05249
4. WO 94/04035
5. WO 94/14963
6. WO 98/26057
7. Murakami et al., JAOCS, Vol. 70, no. 6, pp. 571-574 (June 1993)
8. Green et al., JAOCS, Vol. 75, no. 11, pp. 1519-1526 (1998)
9. Takahashi et al., Biosci. Biotech. Biochem., 59 (5), pp. 809-812, (1995)
10. Binsbergen et al., Peptides pp. 666- 669(1998)
11. Plou et al., Stability and Stabilization of Biocatalysis; pp.115-120 (1998)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record

10/019

531 DECEMBER 03 DEC 2001

therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: December 3, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

FORM PTO-1449
(Rev. 2-12)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No.
5885.204-USSerial No.
To be assignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Callisen et al.Filing Date
December 3, 2001Group
To be assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 258 063	March 2, 1988	EP				
	0 305 216	March 1, 1989	EP				
	94/14963	July 7, 1994	WO				
	92/05249	April 2, 1992	WO				
	98/26057	June 18, 1998	WO				
	94/04035	March 3, 1994	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Green et al., JAOCS, Vol. 75, no. 11, pp. 1519-1526 (1998)
	Murakami et al., JAOCS, Vol. 70, no. 6, pp. 571-574 (June 1993)
	Takahashi et al., Biosci. Biotech. Biochem., 59 (5), pp. 809-812, (1995)
	Binsbergen et al., Peptides pp. 666- 669(1998)
	Plou et al., Stability and Stabilization of Biocatalysis; pp.115-120 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.